Compare BNED & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNED | DCTH |
|---|---|---|
| Founded | 1965 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.0M | 323.1M |
| IPO Year | N/A | N/A |
| Metric | BNED | DCTH |
|---|---|---|
| Price | $7.70 | $9.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 307.6K | ★ 504.2K |
| Earning Date | 03-09-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | 0.03 |
| Revenue | ★ $1,677,191,000.00 | $79,603,000.00 |
| Revenue This Year | N/A | $132.21 |
| Revenue Next Year | N/A | $33.88 |
| P/E Ratio | ★ $162.95 | $269.81 |
| Revenue Growth | 7.64 | ★ 251.54 |
| 52 Week Low | $5.90 | $8.12 |
| 52 Week High | $12.21 | $18.23 |
| Indicator | BNED | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 37.61 | 42.36 |
| Support Level | $8.57 | $8.94 |
| Resistance Level | $9.05 | $10.30 |
| Average True Range (ATR) | 0.47 | 0.52 |
| MACD | -0.17 | -0.08 |
| Stochastic Oscillator | 17.89 | 23.70 |
Barnes & Noble Education Inc is a contract operator of physical and virtual bookstores for college and university campuses and K-12 institutions across the United States. The company is also a textbook wholesaler and inventory management hardware and software provider. It offers course materials through physical and online bookstores, including new and used print textbooks, rental options, digital textbooks, and publisher-hosted digital courseware. Products are also offered directly to students through Textbooks.com. The majority of the company's revenue is derived from the sale of products through its bookstore locations, including virtual bookstores, and the bookstore affiliated e-commerce websites.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.